NEW YORK, March 2 (Reuters) - U.S. pharmaceutical and medical equipment maker Johnson & Johnson said on Monday it agreed to sell its Cordis vascular technology unit to Cardinal Health for $1.9...
NEW YORK, March 2 (Reuters) - Cardinal Health said on Monday that it would buy Johnson & Johnson 's Cordis vascular technology unit for $1.9 billion and that the acquisition would boost 2017 earnings by 20 cents per share.
Cardinal Health announced March 2 that it will acquire Cordis, a cardiology and endovascular device manufacturer from Johnson & Johnson for $1.9 billion. The transaction is expected to close at the end of 2015 and provide earnings accretion in 2017
in the report include 3M Health Care, Bayer AG, Abbott Laboratories, Cardinal Health, Inc., GE Healthcare, Johnson & Johnson Services, Inc., Gentiva Health Services, Inc., Invacare Corporation, F. Hoffmann-La Roche Ltd., Phillips
competitors, such as Novartis NVS , Abbott ABT , and Johnson & Johnson JNJ , but we still believe there will still be attractive ..... place with 10% share, but well behind market leader Johnson & Johnson and its 40% share. The four top firms control approximately
Feb 26 (Reuters) - South Carolina's Supreme Court ordered Johnson & Johnson to pay a penalty of $136 million, upholding a jury's finding that the drugmaker's Janssen unit had improperly marketed its anti-psychotic drug Risperdal and concealed its risks.
Feb 25 (Reuters) - Cancer drug maker Pharmacyclics Inc is exploring a sale and has attracted interest from Johnson & Johnson and Novartis AG, Bloomberg reported.
Feb 25 (Reuters) - Cancer drugmaker Pharmacyclics Inc is exploring a possible sale of the company and has attracted interest from Johnson & Johnson and Novartis AG, Bloomberg reported, citing people familiar the matter.
Feb 17 (Reuters) - Medical device maker Boston Scientific Corp on Tuesday said it has agreed to pay $600 million to Johnson & Johnson to settle a long-running lawsuit over Boston Scientific's 2005 acquisition of rival Guidant.
ratings are unaffected by its recent settlement with Johnson & Johnson ( NYSE : JNJ ) regarding litigation associated with BSX's acquisition ..... The settlement calls for BSX to pay $600 million to JNJ during 2015. BSX will make two $300 million dollar